Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

OLANZAPINE

All products: general benefit

Other products in the same Health Canada class (N05A, N05AH) — coverage varies; not interchangeable

  • Asenapine (Saphris): general benefit
  • Loxapine (Loxapac): general benefit, Not a benefit
  • Quetiapine (Seroquel XR): general benefit, Not a benefit
  • Clozapine (AA-Clozapine Tablet): not a benefit
  • Aripiprazole (Abilify Asimtufii): general benefit
  • Brexpiprazole (Rexulti): general benefit

18 more in the class list below

Zyprexa · DIN 02229269 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Zyprexa · DIN 02229269 Manufacturer: Eli Lilly Canada Inc.; listing date 1997-04-10 Health Canada: Marketed since 2026-02-25 · brand ZYPREXA · ATC N05AH03 OLANZAPINE · form Tablet · route Oral · ingredients OLANZAPINE 5 MG · company Cheplapharm registration gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.3544 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43531 · Verify on the e-Formulary ↗ (DIN 02229269)

Source record
DIN 02229269: Zyprexa Raw flags: sec3=Y Item: 281608187; group id 498; item number 1286; lccId None; manufacturer id LIL Source form: Tab; strength: 5mg Recorded listing: General benefit Source prices (unrounded): $4.6137; ministry $0.3544 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02229269 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43531
Interchangeable products
AG-Olanzapine FC · DIN 02487616 · $0.3544 Apo-Olanzapine · DIN 02281805 · $0.3544 Co Olanzapine · DIN 02325667 · $0.3544 Jamp Olanzapine FC · DIN 02417251 · $0.3544 Mint-Olanzapine · DIN 02410168 · $0.3544 NRA-Olanzapine · DIN 02545594 · $0.3544 Olanzapine · DIN 02372827 · $0.3544 Olanzapine · DIN 02385872 · $0.3544 PMS-Olanzapine · DIN 02303159 · $0.3544 Ran-Olanzapine · DIN 02403072 · $0.3544 Sandoz Olanzapine · DIN 02310368 · $0.3544 Teva-Olanzapine · DIN 02276720 · $0.3544
Shortage status: resolved shortage (ended 2026-02-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02229269
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab

QUETIAPINE

· 128 products · General benefit (125), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 50mg, 150mg, 200mg, 300mg, 400mg, 25mg, 100mg · ER Tab, Tab

CLOZAPINE

· 14 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg, 200mg, 25mg, 100mg ·

ARIPIPRAZOLE

· 70 products · General benefit · strengths: 720mg/2.4mL, 960mg/3.2mL, 300mg/Vial, 400mg/Vial, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg · Inj Sol-Pref Syr, Prolong-Rel Inj Pd-Vial Pk, Tab

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: manic or mixed episodes in bipolar i disorder, schizophrenia and related psychotic disorders
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ARIPIPRAZOLE, PALIPERIDONE, ZIPRASIDONE HCL MONOHYDRATE ARIPIPRAZOLE · General benefit 1 INDICATIONS ABILIFY (aripiprazole) is indicated for:  the treatment of schizophrenia and related psychotic disorders in adults. PM: https://pdf.hres.ca/dpd_pm/00060025.PDF; date February 11, 2021; DIN 02322374; fetched 2026-09-10 Product monograph  the treatment of schizophrenia and related psychotic disorders in adults. In controlled clinical trials, ABILIFY was found to improve both positive and negative symptoms. ABILIFY has been shown to be more effective than placebo in maintaining clinical improvement for up to 26 weeks in adults. PM: https://pdf.hres.ca/dpd_pm/00060025.PDF; date February 11, 2021; DIN 02322374; fetched 2026-09-10 Product monograph  the treatment of manic or mixed episodes in bipolar I disorder in adults. ABILIFY may be used as acute monotherapy or cotherapy with lithium or divalproex sodium when there is an insufficient acute response to these agents alone. ABILIFY as cotherapy with lithium or divalproex sodium has been shown to be more effective than placebo plus mood stabilizer in maintaining clinical improvement for up to 1 year in adult patients with manic or mixed episodes associated with bipolar I disorder (see CLINICAL TRIALS, Trial Design and Study Demographics, Bipolar Disorder). The physician who elects to use ABILIFY for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. PM: https://pdf.hres.ca/dpd_pm/00060025.PDF; date February 11, 2021; DIN 02322374; fetched 2026-09-10 Product monograph PALIPERIDONE · General benefit 1 INDICATIONS INVEGA® (paliperidone) is indicated for the treatment of schizophrenia and related psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00059282.PDF; date December 17, 2020; DIN 02300273; fetched 2026-09-10 Product monograph RISPERIDONE · Listed, not a benefit (12), General benefit (70) 1 INDICATIONS Adults Schizophrenia pms-RISPERIDONE (risperidone) is indicated for the acute treatment and maintenance treatment of schizophrenia and related psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00062538.PDF; date August 13, 2021; DIN 02252007; fetched 2026-09-10 Product monograph ZIPRASIDONE HCL MONOHYDRATE · General benefit 1 INDICATIONS  Schizophrenia ZELDOX (ziprasidone) is indicated for the treatment of schizophrenia and related psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00072509.PDF; date SEP 15, 2023; DIN 02298597; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications ZYPREXA, ZYPREXA ZYDIS (oral olanzapine) is indicated for • the acute and maintenance treatment of schizophrenia and related psychotic disorders. In controlled clinical trials, oral ZYPREXA was found to improve both positive and negative symptoms. Oral ZYPREXA has been shown to be effective in maintaining clinical improvement during 1-year of continuation therapy in patients who had shown an initial treatment response. ZYPREXA, ZYPREXA ZYDIS (oral olanzapine) is indicated for • the acute treatment of manic or mixed episodes in bipolar I disorder (monotherapy or cotherapy) • maintenance treatment in bipolar I disorder (monotherapy). Olanzapine may be used as monotherapy or cotherapy with agents commonly used in the treatment of acute bipolar disorder (e.g., lithium or divalproex sodium). The efficacy of ZYPREXA as monotherapy maintenance treatment in bipolar patients with manic or mixed episodes who responded to acute treatment with ZYPREXA was demonstrated in two 1-year “time to relapse” trials (see 14 Clinical Trials). The physician who elects to use ZYPREXA for extended periods should periodically re-evaluate the long-term usefulness of the dr… https://pdf.hres.ca/dpd_pm/00085079.PDF PM date: 2026-06-16 Source product: ZYPREXA; DIN 02229250; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.